Mf-1

Phase 1

UUniversity of Shizuoka

Mf-1 is one of 2 therapeutic programs targeting PARKINSON DISEASE (Disorder). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

PARKINSON DISEASE (disorder)Recruiting

PARKINSON DISEASE (disorder)Phase 1

Recruiting

Competition

Competitive Landscape

4 competitors in PARKINSON DISEASE (disorder)

#DrugCompanyPhaseTrials

Best Oral Medication

UUniversity Hospital Tuebingen

Phase 3

1 2

Mf-1

UUniversity of Shizuoka

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

PARKINSON DISEASE (disorder)

NCT07666022

Clinical

Trials by Indication[1]

PARKINSON DISEASE (Disorder)1 trial

A Phase I Investigator-initiated First-in-human Study to Evaluate the Safety and Pharmacokinetics of MF1 in Healthy Adults and Patients With Parkinson's Disease (MF1-FIH)

Recruiting·UUniversity of Shizuoka·Phase 1·NCT07666022·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mf-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Mf-1. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Shizuoka company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUniversity of Shizuoka

Mf-1

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

PARKINSON DISEASE (Disorder)1 trial

References

Drug Info

Quick Facts

Related News